scholarly journals Lifestyle Modification and Prevention of Type 2 Diabetes in Overweight Japanese With Impaired Fasting Glucose Levels

2011 ◽  
Vol 171 (15) ◽  
pp. 1352 ◽  
Author(s):  
Toshikazu Saito
Keyword(s):  
Type 2 Diabetes ◽  
Impaired Fasting Glucose ◽  
Lifestyle Modification ◽  
Fasting Glucose ◽  
Glucose Levels

scholarly journals Can the risk of epidemic of prediabetes and diabetes in Poland be reduced?

2020 ◽  
pp. 676-685
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Impaired Fasting Glucose ◽  
21St Century ◽  
Lifestyle Modification ◽  
Fasting Glucose ◽  
Increased Risk

Prediabetes, i.e. impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), are associated with an increased risk of developing type 2 diabetes, cardiovascular deaths, dementia, and cancer (1-4). According to the recommendations of the Polish Diabetes Association, both pre-diabetes and diabetes are indications for lifestyle modification (5). The joint efforts of many specialists in various fields may slow down this epidemic of the 21st century. The aim of the study is to answer the question “Is it possible to reduce the risk of an epidemic of prediabetes and diabetes in Poland?”

scholarly journals From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management

2020 ◽  
Vol 2020 ◽  
pp. 1-10 ◽  
Author(s):  
Arianna Pani ◽  
Ilaria Gironi ◽  
Giacoma Di Vieste ◽  
Elena Mion ◽  
Federico Bertuzzi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Glucose Levels

Aims. Despite the very clear association between polycystic ovary syndrome (PCOS) and dysglycemia, few studies have explored the continuum of glycemic alterations leading from minor glucose abnormalities to overt diabetes. The purpose of this review is to trace the natural history of glycemic alteration in women with PCOS. Methods. We performed a literature review without time limit until August 2019. Inclusion criteria were studies addressing the association between impaired glucose tolerance or impaired fasting glucose or type 2 diabetes (T2D) and PCOS with at least an English abstract. The exclusion criteria were no PCOS or impaired glucose tolerance or impaired fasting glucose or T2D as outcome. The outcomes of interest were the onset of impaired glucose tolerance, impaired fasting glucose, T2D, and the progression from impaired glucose tolerance or impaired fasting glucose to T2D. Results. Healthy diet and physical activity are the first-line therapy for PCOS. Treatment with metformin was associated with significant lower 2-hour postload glucose levels and with reduction in fasting glucose when compared to placebo. Thiazolidinediones were more effective in reducing fasting glucose levels compared to placebo. Metformin and pioglitazone treatments showed similar effects on fasting glucose levels. The sodium-glucose cotransporter-2 inhibitor empagliflozin did not show differences in metabolic parameters when compared to metformin. The combination therapy with metformin plus the glucagon-like peptide-1 receptor agonist liraglutide was associated with significant improvements in basal and postload glucose levels compared with only liraglutide. Likewise, a combination therapy with the dipeptidyl peptidase-4 inhibitor saxagliptin and metformin demonstrated superiority versus metformin in fasting glucose and oral glucose tolerance test normalization. Myo-inositol supplementation was associated with lower insulin levels, glucose levels, and insulin resistance when compared with placebo, metformin, or estrogen treatments. Conclusions. The use of insulin-sensitizing agents, such as metformin and inositols, along with lifestyle interventions may improve the metabolic profile in PCOS women.

scholarly journals PPARD rs7770619 polymorphism in a Korean population: Association with plasma malondialdehyde and impaired fasting glucose or newly diagnosed type 2 diabetes

2018 ◽  
Vol 15 (4) ◽  
pp. 360-363
Author(s):  
Minjoo Kim ◽  
Minkyung Kim ◽  
Hye Jin Yoo ◽  
Yao Sun ◽  
Sang-Hyun Lee ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Plasma Concentrations ◽  
Peroxisome Proliferator ◽  
Newly Diagnosed ◽  
Glucose Levels ◽  
Normal Fasting Glucose ◽  
Plasma Malondialdehyde

Both the peroxisome proliferator-activated receptor delta gene ( PPARD) and malondialdehyde plasma concentrations may play a role in impaired glucose metabolism. The aim of this work was to determine whether PPARD is a candidate gene for impaired fasting glucose or type 2 diabetes and whether a particular genetic variant shows association with plasma malondialdehyde levels. Among the 10 single-nucleotide polymorphisms that were most strongly associated with malondialdehyde, the rs7770619 polymorphism in PPARD was analysed in 1798 subjects with normal fasting glucose, impaired fasting glucose and newly diagnosed type 2 diabetes. Our data demonstrate that the CT genotype of the rs7770619 is associated with a lower risk of impaired fasting glucose or type 2 diabetes together with lower plasma levels of malondialdehyde in both groups ( p < 0.05). Glucose levels and the rs7770619 are significantly associated in individuals with normal fasting glucose, and a trend towards an association between glucose levels and rs7770619 is also observed in individuals with impaired fasting glucose or type 2 diabetes. In conclusion, PPARD rs7770619 is a novel candidate variant for impaired fasting glucose and type 2 diabetes and shows association with malondialdehyde levels. Future work is required to understand the mechanisms for these associations and the clinical implications of our findings.

Circulating Netrin-1 as a Novel Biomarker for Impaired Fasting Glucose and Newly Diagnosed Type 2 Diabetes Mellitus

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1535-P ◽  
Author(s):  
HYE-IN JUNG ◽  
JAEHYUN BAE ◽  
EUGENE HAN ◽  
GYURI KIM ◽  
JI-YEON LEE ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Newly Diagnosed

1476-P: Progression to Type 2 Diabetes from Normal or Impaired Fasting Glucose

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1476-P
Author(s):  
AOIFE M. EGAN ◽  
CHRISTINA WOOD-WENTZ ◽  
KENT R. BAILEY ◽  
ADRIAN VELLA
Keyword(s):  
Type 2 Diabetes ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose
Sign in / Sign up

Export Citation Format

Share Document